A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely led to rapid and sustained inhibition of the kallikrein protein in healthy adults, according to preliminary data from a Phase 1a trial. “STAR-0215 has shown early proof of concept for…
News
PHVS416, an investigational oral therapy being developed by Pharvaris, was shown to be safe and effective in treating swelling attacks in patients with hereditary angioedema (HAE). The therapy substantially reduced symptoms, particularly skin swelling, skin pain, and abdominal pain. It also significantly shortened how…
A 64-year-old woman in Japan was diagnosed with hereditary angioedema (HAE) type 1 after being hospitalized with severe recurrent epigastric pain — pain in the upper abdomen, in the area below the ribs. Researchers said this case highlights the need to…
Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), shows promise for treating idiopathic angioedema, according to data from a small Phase 4 trial. In the study, treatment for roughly six months with Xolair as an add-on therapy lessened disease activity when compared to…
Takhzyro (lanadelumab), an under-the skin injection therapy to prevent attacks in people with hereditary angioedema (HAE), has won the 2022 Prix Galien Canada Innovative Product Award. The prestigious annual award is given to a company — here, Takeda Pharmaceuticals — in recognition of a marketed product that has “made the most…
Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE)Â in Israel can now receive once-daily Orladeyo (berotralstat) to prevent HAE-related swelling attacks. The decision to approve the medication by the Israeli Ministry of Health follows similar decisions in Canada and Switzerland, as well as…
Donidalorsen, a small molecule therapy being developed by Ionis Pharmaceuticals, continues to be safe and to prevent swelling attacks when taken for up to one year by people with hereditary angioedema (HAE), trial data show. The open-label extension study (NCT04307381) is ongoing in patients who completed a placebo-controlled…
A single dose of the extended-release formulation of PHA121 — an investigational molecule under development for the prevention and treatment of swelling attacks associated with hereditary angioedema (HAE) — led to sustained, therapeutic levels of the medication in the bloodstream of participants. That’s according to promising data from…
Most hereditary angioedema (HAE) patients in a Phase 1/2 clinical trial have gone months without a swelling attack following a single infusion of the experimental gene-editing therapy NTLA-2002. The remaining patients haven’t yet reached the pre-specified 16-week follow-up period for their attack rates to be analyzed, but their comparable…
People with hereditary angioedema (HAE) who switched to Orladeyo (berotralstat) from other preventive treatments generally experience a reduction in swelling attacks. That is according to real-world data presented by BioCryst Pharmaceuticals, Orladeyo’s developer, during the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma…
Recent Posts
- New treatment cuts swelling attacks in early hereditary angioedema trial
- Over 90% reduction in HAE attacks seen with 3 years of deucrictibant in testing
- Now I know why my parents were so exhausted
- Ekterly tablets replacing injections for many in HAE attacks: New data
- Why it’s important to maintain your own personal health information, part 2